In this HCC CONNECT podcast HCC Experts Prof. Matthias Pinter and Prof. Jeroen Dekervel, discuss and debate the clinical implications of new HCC Phase 3 clinical trials data presented and discussed at the ILCA and ESMO congresses. They discuss Immuno-oncology agents and their place in the upcoming updated guidance such as the proposed new ILCA Systemic Therapies Guidance algorithm. They also discuss new treatment options in first line for advanced HCC presented at ESMO including the three late breaking abstracts LEAP-002, RATIONALE-301 and tislelizumab monotherapy trials. The latter two studying first-line treatment with an anti-PD1 antibody with or without a kinase inhibitor in patients with advanced hepatocellular carcinoma. The experts evaluate and provide their insights into how to integrate these new treatments for HCC in the clinical practice.
In this podcast, the experts give an overview of the EMERALD trial and present elacestrant as the first, and currently only, oral SERD to...
What are the common pre-analytical phase challenges in lung cancer, and how can we overcome them? Why is it important to identify genetic alterations?...
What treatment options are available for patients with metastatic colorectal cancer who have already progressed through multiple lines of therapy? How can we select...